Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination

Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination

Abstract Several inhibitors of programmed cell death-1 (PD-1) and programmed death ligand-1 (PD-L1) have been approved as a form of immunotherapy for multiple cancers. Ionizing radiation therapy (RT) has been shown to enhance the priming and effector phases of the antitumor T-cell response rendering...

Full description

Bibliographic Details
Main Authors: Jun Gong, Thang Q. Le, Erminia Massarelli, Andrew E. Hendifar, Richard Tuli
Format: Article
Language:English
Published: BMJ Publishing Group 2018-06-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Radiation therapy
PD-1
PD-L1
Clinical trials
Preclinical
Antitumor
Online Access:http://link.springer.com/article/10.1186/s40425-018-0361-7

Internet

http://link.springer.com/article/10.1186/s40425-018-0361-7

Similar Items